Skip to main content
Journal cover image

PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer

Publication ,  Journal Article
Vidal, AC; Henry, NM; Murphy, SK; Oneko, O; Nye, M; Bartlett, JA; Overcash, F; Huang, Z; Wang, F; Mlay, P; Obure, J; Smith, J; Vasquez, B ...
Published in: Clinical and Translational Oncology
March 1, 2014

Introduction: Although most invasive cervical cancer (ICC) harbor <20 human papillomavirus (HPV) genotypes, use of HPV screening to predict ICC from HPV has low specificity, resulting in multiple and costly follow-up visits and overtreatment. We examined DNA methylation at regulatory regions of imprinted genes in relation to ICC and its precursor lesions to determine if methylation profiles are associated with progression of HPV-positive lesions to ICC. Materials and methods: We enrolled 148 controls, 38 CIN and 48 ICC cases at Kilimanjaro Christian Medical Centre from 2008 to 2009. HPV was genotyped by linear array and HIV-1 serostatus was tested by two rapid HIV tests. DNA methylation was measured by bisulfite pyrosequencing at regions regulating eight imprinted domains. Logistic regression models were used to estimate odd ratios. Results: After adjusting for age, HPV infection, parity, hormonal contraceptive use, and HIV-1 serostatus, a 10 % decrease in methylation levels at an intragenic region of IGF2 was associated with higher risk of ICC (OR 2.00, 95 % CI 1.14-3.44) and cervical intraepithelial neoplasia (CIN) (OR 1.51, 95 % CI 1.00-2.50). Methylation levels at the H19 DMR and PEG1/MEST were also associated with ICC risk (OR 1.51, 95 % CI 0.90-2.53, and OR 1.44, 95 % CI 0.90-2.35, respectively). Restricting analyses to women >30 years further strengthened these associations. Conclusions: While the small sample size limits inference, these findings show that altered DNA methylation at imprinted domains including IGF2/H19 and PEG1/MEST may mediate the association between HPV and ICC risk. © 2013 The Author(s).

Duke Scholars

Published In

Clinical and Translational Oncology

DOI

EISSN

1699-3055

ISSN

1699-048X

Publication Date

March 1, 2014

Volume

16

Issue

3

Start / End Page

266 / 272

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1111 Nutrition and Dietetics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vidal, A. C., Henry, N. M., Murphy, S. K., Oneko, O., Nye, M., Bartlett, J. A., … Hoyo, C. (2014). PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer. Clinical and Translational Oncology, 16(3), 266–272. https://doi.org/10.1007/s12094-013-1067-4
Vidal, A. C., N. M. Henry, S. K. Murphy, O. Oneko, M. Nye, J. A. Bartlett, F. Overcash, et al. “PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer.” Clinical and Translational Oncology 16, no. 3 (March 1, 2014): 266–72. https://doi.org/10.1007/s12094-013-1067-4.
Vidal AC, Henry NM, Murphy SK, Oneko O, Nye M, Bartlett JA, et al. PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer. Clinical and Translational Oncology. 2014 Mar 1;16(3):266–72.
Vidal, A. C., et al. “PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer.” Clinical and Translational Oncology, vol. 16, no. 3, Mar. 2014, pp. 266–72. Scopus, doi:10.1007/s12094-013-1067-4.
Vidal AC, Henry NM, Murphy SK, Oneko O, Nye M, Bartlett JA, Overcash F, Huang Z, Wang F, Mlay P, Obure J, Smith J, Vasquez B, Swai B, Hernandez B, Hoyo C. PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer. Clinical and Translational Oncology. 2014 Mar 1;16(3):266–272.
Journal cover image

Published In

Clinical and Translational Oncology

DOI

EISSN

1699-3055

ISSN

1699-048X

Publication Date

March 1, 2014

Volume

16

Issue

3

Start / End Page

266 / 272

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1111 Nutrition and Dietetics